The US peptide status index
Peptide America is a reference index. For each molecule it records whether an FDA-approved product exists, whether a licensed 503A pharmacy may compound it, or whether no lawful route exists at all — each posture dated, sourced to the primary record, and re-verified when the ground moves. It moved twice in 2026.
Some outbound links are partner links — how this reference is funded. Nothing here is medical advice.
62 dated entries across 7 months of 2026, one column per month, counted by how many molecules the record moved. The tallest column is 14.
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule.
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule.
Recent research
The whole index in one view. A posture is a legal position on a date, not a judgment about whether a molecule works.
6 of the 7 substances the Pharmacy Compounding Advisory Committee reviewed won a recommendation to be added to the section 503A bulks list. None of them may be compounded today. A recommendation is advisory; only an FDA final rule changes what a pharmacy may do, and none has issued.
Every tally above is a reported figure, not a primary one: FDA has published no minutes, transcript or vote summary for the meeting. Each is attributed on the molecule’s own page, where two independent accounts are cited and agree. The full vote ledger.
6 of the 15 molecules with a lawful route have a supplier this index has read and dated; 9 are lawful and have none yet. No supplier is listed for any of the 25 without a lawful route; the partner card on each page names no molecule.
Partner programs; this reference earns a commission on starts. How this reference is funded.
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide.
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates.
Category 1 of the interim 503A bulks list; compoundable with a valid prescription.
Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route.
27 suppliers across 6 molecules. Nothing here is a recommendation, no supplier pays for a status, and no supplier is listed for a molecule without a lawful route.
Each one answers a single question and shows the records it was answered from.
The underlying record, assembled once and cited — several of these exist nowhere else.
The same index cut the other way, by what a molecule is rather than what the law says about it.